A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ADAb / anti-drug antibodies

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ADAb  (>> Co-occurring Abbreviation)
Long Form:   anti-drug antibodies
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease. ADM, IBD, IFX, LOR, TNF
2022 Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. CI, NOR-DRUM, OR, RA, SpA, TDM, TNF
2021 Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA. RA
2021 Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. axSpA, BASDAI, MASES, TNF
2021 Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. ADM, IFX, TDM, TNF
2020 Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. ACR20, ADA, ETN, INF, IRRs, ISRs, RA
2020 Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. ADL, ETA, IFX, RA, TNFi
2019 Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. ADA, HAQ, PsA, TNFi
2019 Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits. IBD, IFX, s-IFXt
10  2018 Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. anti-TNF, ITABIO, LLS, PD, RA
11  2017 Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. CD, NONMEM, PK, V/F
12  2017 An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients. ACPA, ELISA, IFX, RA, RF
13  2017 Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar - Preliminary report. ELISA, ETN, RA
14  2017 Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. AS, JIA, nr-axSpA, Ps, PsA, RA, RA
15  2017 Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. AUC, DL, RA, ROC
16  2017 Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. TDM, TNF, UC
17  2016 A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. TNFi
18  2016 Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis. TNF
19  2014 Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. ---
20  2014 Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. EULAR, RA
21  2013 A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. GEE, RA, TNFi
22  2013 Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. ABT, AS, BASDAI, CRP
23  2012 Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. TNF
24  2006 Confirming human antibody responses to a therapeutic monoclonal antibody using a statistical approach. QC
25  1996 Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. anti-MTX Fab, anti-MTX IgG, MTX